A Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer.
Latest Information Update: 16 Dec 2019
At a glance
- Drugs Bortezomib (Primary) ; Doxorubicin
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 08 Aug 2011 Planned end date changed from Mar 2009 to Oct 2009 as reported by ClinicalTrials.gov.
- 08 Aug 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 22 Oct 2008 Status changed from discontinued to suspended as reported by ClinicalTrials.gov.